8:30-9:45 Session 3: Biology of breast cancer II: Tumor heterogeneity and disease segmentation in breast cancer |
议程3:乳腺癌生物学II:乳腺癌的肿瘤异质性和疾病划分 |
主持:Fraser W. Symmans,Jonas Bergh |
Intratumor heterogeneity: Targeting multiple trunk and branch drivers in breast cancer |
讲者:Charles Swanton |
肿瘤内异质性:靶向于乳腺癌的多个主要和次要驱动因素 |
Heterogeneity of Triple Negative subtype: Gene expression profile and phenotype |
讲者:Brian D. Lehmann |
三阴性乳腺癌的异质性:基因表达谱和表型 |
Molecular segmentation in Luminal breast cancer: How to select the driver pathways |
讲者:Sherene Loi |
luminal型乳腺癌的分子分类:如何选择驱动通路 |
Insights in biology of luminal HER2 vs. enriched HER2 subtypes: Therapeutic implications |
讲者:Nadja Harbeck |
思考luminal HER-2与富集HER-2亚型之间的生物学特征:对治疗的启示 |
讨论 |
|
9:45-10:45 Session 4: Biology of breast cancer III: Genome remodeling and tumor microenvironment |
议程4:乳腺癌生物学III:基因组重构和肿瘤微环境 |
主持:Mitch Dowsett,Daniel F. Hayes |
Tumor-stroma crosstalk: Targeting stroma and inflammation |
讲者:Frances Balkwill |
肿瘤与基质的相互作用:靶向于基质和炎症 |
Immune-pathways and immunome as a target |
讲者:Giuseppe Curigliano |
可作为目标的免疫通路和免疫组 |
Targeting bone microenvironment: Clinical implications |
讲者:Michael Gnant |
靶向于骨微环境:临床启示 |
讨论 |
|
11:20-12:30 Session 5: Bridging clinic with biology: Emerging drugable pathways on the horizon |
议程5:链接临床和生物学:药物开发即将成功的通路 |
主持:Giuseppe Curigliano,Clifford Hudis |
Targeting CDK 4-6 pathway |
讲者:Richard S. Finn |
靶向CDK4-6通路 |
Targeting DNA repair pathways |
讲者:Andrew Tutt |
靶向DNA修复通路 |
Targeting PIK3CA pathway |
讲者:José Baselga |
靶向PIK3CA通路 |
Targeting FGFR pathway |
讲者:Nicholas Turner |
靶向FGFR通路 |
讨论 |
|
14:00-15:00 Session 6: Primary prevention, metabolism and genetics |
议程6:一级预防,代谢和遗传学 |
主持:John F. Forbes,Marco Colleoni |
Using germline genetics in the management of breast cancer patients and their families |
讲者:Judy Garber |
利用生殖细胞遗传学管理乳腺癌患者及其亲属 |
Preventing invasive breast cancer in women at high risk based on benign/in situ pathology |
讲者:Jack Cuzick |
基于良性或原位病变预防高危女性侵袭性乳腺癌的发生 |
Obesity and insulin resistance: Correlations and time course of prognostic associations |
讲者:Pamela J. Goodwin |
肥胖和胰岛素抵抗:与预测作用的关系和时间进程 |
讨论 |
|
15:00-16:15 Session 7: Beyond pathology of breast cancer in 2015 |
议程7:乳腺癌病理学在2015年的新拓展 |
主持:Giuseppe Viale; Hervé Bonnefoi |
The special case of “equivocal” pathological biomarkers (ER, PgR and HER2): Implications for breast cancer treatment |
讲者:Fraser W. Symmans |
病理学标志物模棱两可的特殊案例(ER,PgR和HER-2):对乳腺癌治疗的启示 |
BCL-2: A new therapeutic target in estrogen receptor-positive breast cancer? |
讲者:Geoffrey J. Lindeman |
BCL-2:雌激素受体阳性乳腺癌的新治疗靶点? |
The changing role of ER in endocrine resistance |
讲者:C. Kent Osborne |
ER在内分泌耐药中的角色转变 |
Developing Ki-67 as a useful marker |
讲者:Carsten Denkert |
将Ki-67开发成为有用标志物 |
讨论 |
|
16:45-18:00 Session 8: Primary systemic therapy of early breast cancer |
议程8:早期乳腺癌的一线全身治疗 |
主持:Eric Winer; Giuseppe Curigliano |
Primary systemic therapy for clinicians: Medical and research perspectives |
讲者:Sybille Loibl |
临床医生从医疗和研究角度看待一线全身治疗 |
Clinical usefulness and relevance of intermediate endpoints for cytotoxic primary systemic therapy |
讲者:Gunter von Minckwitz |
细胞毒性一线全身治疗的中期终点临床应用和意义 |
Clinical trial designs in the neoadjuvant setting: Challenges of the genomic era |
讲者:Lisa Carey |
新辅助治疗的临床试验设计:来自基因组时代的挑战 |
讨论 |
|